In the Boardroom
Refine Search
Pharmaceutical
Some four months after resigning from his role as physician-in-chief at Memorial Sloan Kettering Cancer Center (MSK) and stepping down from the board of US pharma major Bristol-Myers Squibb, José Baselga has been given another chance. 7 January 2019
Pharmaceutical
Peter Guenter has sought to keep up the pace of his turnaround of Spanish dermatology specialist Almirall. 4 January 2019
Pharmaceutical
US biopharma major AbbVie and Tizona Therapeutics, a privately-held immunotherapy company, have entered into a global, strategic collaboration to develop and commercialize CD39-targeted therapeutics, including TTX-030, a first-in-class antibody for the treatment of cancer. 3 January 2019
Biotechnology
UK clinical-stage biopharma firm Verona Pharma today announced the expansion of its global clinical development team with the appointment of Kathleen Rickard as chief medical officer, and Tara Rheault as vice president of R&D operations and global project management. 3 January 2019
Pharmaceutical
Recently-established Roivant Sciences company Altavant Sciences, which is focused on clinical development of novel therapies for pulmonary arterial hypertension and other indications, today announced the appointment of Lyn Baranowski as chief operating officer. 2 January 2019
Pharmaceutical
Swiss pharma giant Novartis announced today that Susanne Schaffert, currently president of its Advanced Accelerator Applications (AAA) business, has been appointed chief executive of Novartis Oncology. 20 December 2018
Biotechnology
US biotech firm Semma Therapeutics today announced the appointments of: David Lebwohl as chief medical officer; David DiGiusto as chief technology officer; and Ann Darda as head of human resources. 19 December 2018
Pharmaceutical
US biopharma company AbbVie today announced a new executive leadership team structure designed to streamline its organizational structure and support its long-term growth strategy. 17 December 2018
Pharmaceutical
In terms of boardroom changes news last week, Gilead Sciences’ poaching of Roche Pharma head as its new chief executive attracted a great deal of attention. On the clinical trial front, there were disappointments for AstraZeneca, which reported another failure with its immuno-oncology drug Imfinzi, and for Axovant Sciences, which is dropping further development of its neurological candidate nelotanserin due to a Phase II failure. Meantime, on deal-making, despite its own failures in the Alzheimer’s space, Eli Lilly has entered into a licensing agreement to take over AC Immune’s investigational drug ACI-3024. 15 December 2018
Pharmaceutical
Mark Timney has been named as the new chief executive of The Medicines Company. 12 December 2018
Biotechnology
Japanese biotech firm Sosei Group today announced that its board of directors, at a meeting held on December 11, 2018, approved a change in its president and chief executive (CEO). 12 December 2018
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has named David Ricks, the chairman and chief executive of US pharma major Eli Lilly, as its new president. 11 December 2018
Pharmaceutical
Adam Schechter, president of Global Human Health (GHH) at US pharma giant Merck & Co, is stepping down from his current position as of December 31, 2018, and will be shifting to an advisory capacity to the chief executive. 11 December 2018
Biotechnology
Following the previously-announced plans of John Milligan to step down from the top post by year-end, US biotech major Gilead Sciences has named Daniel O'Day as chairman and chief executive, effective March 1, 2019. 10 December 2018
Pharmaceutical
Daniel O'Day, chief executive of Roche Pharmaceuticals and member of the Roche corporate executive committee, will be stepping down from his role as of December 31, 2018. 10 December 2018
Pharmaceutical
Ireland-headquartered pioneering inflammasone company Inflazome has announced the appointment of Dr Thomas Jung as its chief medical officer. 30 November 2018
Pharmaceutical
Marco Cerato has left privately-held Swiss drugmaker Helsinn to join the Mundipharma network of independent associated companies. 28 November 2018
Biotechnology
Israel and USA-based biotech Anchiano Therapeutics today announced the appointment of David Kerstein, as the company’s new chief medical officer (CMO). 27 November 2018
Biotechnology
Greg MacMichael, the former global head of cell and gene therapy technical development and manufacturing at Swiss pharma giant Novartis, is one of five new recruits to join Axovant Sciences. 26 November 2018
Biotechnology
With current Gilead Sciences chief executive John Milligan standing down at the end of the year, the announcement on his successor is one of the most eagerly-awaited in biopharma at present. 21 November 2018
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Pharmaceutical
British artificial intelligence specialist BenevolentAI has announced the return of its founder, Ken Mulvany, as executive chairman. 18 October 2024
Biotechnology
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
Pharmaceutical
Canada-based biotech Sernova (TSX: SVA) has announced key new appointments to its executive leadership team. 15 October 2024
Biotechnology
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Pharmaceutical
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Biotechnology
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Biotechnology
French cancer vaccine focused biotech Oncovita has appointed Dr Stéphane Altaba as its new chief executive (CEO). 9 October 2024
Biotechnology
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Biotechnology
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Pharmaceutical
US pharma giant Pfizer (NYSE: PFE) has announced that John McGinley has been appointed UK managing director and country president. 7 October 2024
Pharmaceutical
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze